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Abstract
Background: Impaired glucose tolerance (IGT) is associated with increased cardiovascular risk.
The pathophysiological mechanisms linking post-challenge hyperglycemia to accelerated
atherosclerosis, however remain to be elucidated.
Methods: A prospective, open, randomised, cross-over study was performed to investigate the
effect of 2 mg repaglinide on hyperglycemia and endothelial function during an oral glucose
tolerance test (75 g glucose) in 12 subjects with diagnosed IGT. Blood samples for determination
of plasma glucose were drawn fasting, 1 and 2 hours after glucose ingestion. Endothelial function
was assessed by measuring flow-mediated dilatation (FMD) of the brachial artery with high-
resolution ultrasound.
Results: Administration of repaglinide resulted in a significant reduction of plasma glucose at 2
hours (172.8+/-48.4 vs. 138.3+/-41.2 mg/dl; p < 0.001). The flow-mediated dilatation (FMD) 2 hours
after the glucose-load was significantly reduced in comparison to fasting in the control group
(6.21+/-2.69 vs. 7.98+/-2.24 %; p = 0.028), whereas after theadministration of repaglinide the FMD
was not significantly different to fasting values (7.24+/-2.57 vs. 8.18+/-2.93 %; p = n.s.). Linear and
logistic regression analysis revealed that only the change of glucose was significantly correlated to
the change of FMD observed (p < 0.001). Regression analysis after grouping for treatment and time
confirmed the strong negative association of the changes of plasma glucose and FMD and indicate
that the effect of repaglinide observed is based on the reduction glycemia.
Conclusion: In subjects with IGT, the endothelial dysfunction observed after a glucose challenge
is related to the extent of hyperglycemia. Reduction of hyperglycemia by repaglinide reduces
endothelial dysfunction in a glucose dependent manner.
Background
Hyperglycemia, across its entire range including non-dia-
betic values is established as a strong and independent
risk factor for cardiovascular morbidity and mortality[1].
In addition, the DECODE study recently established that
acute post-challenge glucose concentration, as measured
during a standardized glucose tolerance test (oGTT), is a
better predictor of risk than fasting glucose also in the
non-diabetic range[2]. The mechanisms that link post-
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challenge hyperglycemia to accelerated atherosclerosis,
however, remain to be further elucidated.
Endothelial dysfunction (ED) represents a very early step
in the development of atherosclerosis[3]. The reduced
nitric-oxide mediated, endothelium-dependent vasodila-
tation occurring in ED is a predictor of cardiovascular risk
in high risk subjects[4] and its improvement seems to pre-
dict treatment-induced risk reduction. In diabetic subjects
ED already occurs in the fasting state and is aggravated for
hours postprandially or in the setting of a glucose-chal-
lenge[5]. Patients with impaired glucose tolerance (IGT)
on the other hand, most commonly have a normal
endothelial function in the fasting state and transient ED
during acute hyperglycemia following a glucose-chal-
lenge[6]. Although several experimental studies suggest
that acute changes of glycemia might lead to endothelial
dysfunction[7], it remains to be investigated whether the
ED observed following a carbohydrate load is caused by
or only associated to hyperglycemia.
Consequently, the aim of our study was to investigate,
whether reduction of post-challenge glucose-excursions
with repaglinide, a short-acting non-sulfonylurea insulin
secretagogue influences endothelial function during an
oGTT in patients with IGT.
Methods
A prospective, randomised, observer-blinded, cross over
study was performed to investigate the effect of 2 mg repa-
glinide on hyperglycemia and endothelial function dur-
ing an oGTT (75 g glucose dissolved in 300 ml water). 12
subjects (10 males, age 62 ± 4 years, BMI 29.4 ± 5.2 kg/m2,
waist/hip ratio 0.93 ± 0.03) with IGT according to the
WHO-criteria and free of clinically manifest vascular dis-
ease were recruited in the study. BMI had to be below 35
kg/m2. Blood pressure had to be below 160/90 mmHg at
the occasion of investigation. Eventually existing antihy-
pertensive and lipid-lowering medication had to be stable
for at least 8 weeks prior and during the study period. On
the examination days patient did not take their concomi-
tant medication and smoking was not allowed within 12
hours before the investigations. The study was approved
by the local ethics committee and conducted according to
the declaration of Helsinki. Signed informed consent was
obtained from all subjects prior to study entry.
Subjects were scheduled to undergo investigations at two
different occasions, separated by 7 ± 2 days, with or with-
out administration of 2 mg repaglinide at the beginning
of the oGTT. Blood sampling and examination of vascular
function was performed in the fasting state and repeated
1 and 2 hours after the glucose load. Endothelial function
was assessed by measuring flow-mediated dilatation
(FMD) of the brachial artery by high-resolution ultra-
sound as established[8,9] and according to recent local
guidelines[10]. Briefly the brachial artery was scanned
longitudinally with a linear transducer (7.5 MHz, Acuson
Sequoia, Siemens GmbH, Austria) proximal to the antecu-
bital fossa. Depth and gain settings were optimised at the
beginning of the examination and the optimal position of
the transducer was marked on the skin. All measurements
were performed R-wave triggered at the end of diastole.
The mean of 3–4 measurements from a stored image was
used as baseline diameter. FMD was induced by supra-
systolic (>250 mmHg) inflation of a blood pressure cuff,
positioned at the forearm, for 5 minutes. Post-ischemic
diameter was determined 45–60 seconds after deflation of
the cuff at the same position as baseline again from 3–4
measurements and FMD (in%) was calculated (100-(post-
ischemic diameter*100/baseline diameter)). At the occa-
sion of the third measurement 2 hours after glucose-chal-
lenge also endothelium-independent vasodilatation
(NMD) was assessed 4 minutes after administration of 0,4
mg nitroglycerin sublingually. Statistical analysis was per-
formed on an Apple Macintosh using the JMP statistic
package (version 5, SAS, Heidelberg, Germany). Compar-
isons were performed using a paired Student's t-test and a
p < 0.05 was considered statistically significant. Linear
and logistic regression analysis was performed to investi-
gate associations between glycemia and endothelial func-
tion.
Glucose and FMD Figure 1
Glucose and FMD Association between the change of glu-
cose as well as the change of FMD in the study population 
grouped according to time and treatment (error bars repre-
sent standard deviation)
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Results
As to be expected, pronounced hyperglycemia was
observed during the oGTT. Administration of repaglinide
resulted in a reduction of plasma glucose at 2 hours dur-
ing the oGTT, accompanied by increased plasma insulin
concentration (Tab.1) whereas no effect of the drug could
be observed 1 hour after beginning of the test. Flow medi-
ated dilation decreased significantly after 1 hour in both
groups. After 2 hours no significant difference from fast-
ing baseline was observed when repaglinide was adminis-
tered and borderline significance was observed in
comparison to the control experiments. In the control
group, however, FMD was still significantly reduced at 2
hours. Linear and logistic regression analysis indicated
that only the change of glucose was significantly corre-
lated to the change of FMD observed (r: -0.566, p <
0.001). No influence of insulin levels, lipids, age, antihy-
pertensive- or lipid-lowering treatment was detected (data
not shown). Regression analysis after grouping for treat-
ment and time (Fig. 1) confirmed the strong negative
association of the changes of plasma glucose and FMD
respectively and indicated that the beneficial effect of
repaglinide observed after 2 hours is based on the reduc-
tion of glycemia. No effect of repaglinide in comparison
to control was observed with regard to nitroglycerin-
mediated, endothelium-independent vasodilatation (Tab.
1).
Discussion
Experimental studies, supporting the epidemiological evi-
dence, established that acute hyperglycemia induces sev-
eral additional proatherogenic mechanisms beside ED
such as haemostatic alterations, platelet activation,
increases of C-reactive protein, expression of adhesion
molecules (for review see 11), as well as activation of
NFkb[7].
It has been established before that acute hyperglycemia
induced by carbohydrate intake is able to induce transient
ED in normal subjects and even more pronounced in sub-
jects with IGT[6]. Our study provides evidence that this
ED in subjects with IGT is caused by acute postchallenge
hyperglycemia and can be prevented by reduction of
hyperglycemia. Thus our results extend and confirm those
of Ceriello et al. who provided such evidence in subjects
with manifest diabetes using subcutaneous insulin as
therapeutic strategy[12]. Further recent evidence for the
contribution of postprandial glucose to ED comes from a
recent study comparing repaglinide and glibenclamide in
dietary treated diabetic subjects[13] showing that only
repaglinide was able to reduce postprandial glycemia,
markers of oxidative stress as well as ED. Insulin itself has
been described to induce vasodilatation acutely as well as
under chronic conditions. We do, however, not expect
that the effect observed during repaglinide treatment is
based on an opposing effect of higher insulin levels amel-
iorating the deleterious effect of hyperglycemia since
regression analysis did not exhibit an association between
changes of insulin and FMD during the oGTT whereas a
highly significant correlation was observed between
changes of glucose and FMD.
Our study, however, has several limitations. First, the sample
size was rather small and the study was performed in an
open design. Second, we observed a somewhat unexpected
weak antihyperglycemic effect of repaglinide. We suggest
this to be due to the fact that an oGTT instead of a mixed
meal was used to induce hyperglycemia. Glucose absorption
under these conditions is much faster and was not paralleled
by increased insulin release induced by repaglinide. It can be
speculated that the effect of repaglinide would have been
more pronounced using a mixed meal. Under such condi-
tions, however, additional effects of hyperlipidemia on
ED[14] could not have been excluded. Finally given the
strong correlation between postchallenge hyperglycemia
Table 2: Plasma insulin and glucose levels as well as FMD during 
the oGTT (comparisons by paired Student's test, data represent 
mean ± standard deviation, #median)
repaglinide control p
Fasting Insulin (mU/l) 7.16 ± 4.79 13.06 ± 20.97 n.s.
1 hour Insulin (mU/l) 72.40 ± 62.35 58.32 ± 48.39 n.s.*
2 hour Insulin (mU/l) 120.71 ± 86.78 49.83 ± 36.09 0.013*
Fasting glucose (mg/dl) 106.58 ± 12.38 109.1 ± 16.3 n.s.
1 hour glucose (mg/dl) 222.08 ± 30.05 213.7 ± 29.9 n.s.*
2 hour glucose (mg/dl) 138.33 ± 41.19 172.8 ± 48.4 <0.001***
Fasting FMD (%) 8.18 ± 2.93 7.98 ± 2.24 n.s.
1 hour FMD (%) 5.50 ± 3.11 5.58 ± 2.91 n.s.*
2 hour FMD (%) 7.24 ± 2.57 6.21 ± 2.69 n.s. (0.102)**
1 hour change FMD (%)# -2.25 -1.95 n.s.*
2 hour change FMD (%)# -1.05 -1.6 n.s.*
Fasting NMD (%) 15.09 ± 3.76 15.58 ± 3.74 n.s.
*p < 0.001 vs. fasting for both groups
**p = 0.028 vs. fasting for control, n.s. for repaglinide
***p < 0.001 vs. fasting for control, p = 0.005 for repaglinide
Table 1: Characteristics of study population including glucose 
values during the OGTT (without repaglinide)
Gender (male/female) 10/2
Age (years) 62 ± 4
BMI (kg/m2) 29.4 ± 5.2
Waist/hip ratio 0.92 ± 0.03
Blood pressure (mmHg) 132 ± 12/79 ± 8
Total cholesterol (mg/dl) 220 ± 52
LDL cholesterol (mg/dl) 136 ± 45
HDL cholesterol (mg/dl) 52 ± 12
Triglycerides (mg/dl) 253 ± 126
Fasting glucose (mg/dl) 109 ± 16
1 hour glucose (mg/dl) 214 ± 30
2 hour glucose (mg/dl) 173 ± 48Publish with BioMed Central    and   every 
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and postprandial hyperglycemia[15] we suggest the applica-
bility of our results to daily life conditions of subjects with
IGT.
Conclusion
In subjects with IGT, endothelial dysfunction observed
after a glucose challenge is related to the extent of hyperg-
lycemia. Reduction of hyperglycemia by repaglinide amel-
iorates endothelial dysfunction in a glucose dependent
manner. These results together with the existing evidence,
in our opinion, justify long term investigations into pre-
vention of vascular disease in subjects with IGT by reduc-
tion of postprandial hyperglycemia.
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